Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal BMD Safety Study in Secondary Hypogonadism
NCT01619683Phase 3Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Sep 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in secondary hypogonadism (HH) comparing Androxal with Placebo (2 arms). Primary endpoint: Bone Mineral Density at 52 weeks. Started Sep 2012; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT01619683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619683.